Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.
FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC
FDA Approval Insights: Ponatinib in Ph+ ALL
Commitments to AML Research Uncover Numerous Targets in Relapsed/Refractory Disease
CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
EMA Validates MAA for Frontline Nivolumab/Ipilimumab for MSI-H/dMMR mCRC
Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer